Minimum target prices for production of direct acting antivirals and associated diagnostics to combat Hepatitis C Virus [PDF]
, 2014 Combinations of direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naïve patients. Mass treatment programs to cure HCV in developing countries are only feasible if the costs of treatment and laboratory ...
Cooke, GS +6 more
core +2 more sources
Archives of Medical Science, 2019 Introduction Non-cirrhotic treatment-naive hepatitis C patients infected with genotype 1 can be treated with ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks, but in practice this regimen is frequently extended up to 12 weeks at least in part due to ...
Dorota Zarębska-Michaluk +26 more
doaj +1 more source
The Turkish Journal of Gastroenterology, 2021 Background: In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice. Methods: Data from patients with chronic hepatitis C treated with SOF/LDV ±
Neşe Demirtürk +40 more
doaj +1 more source
Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]
, 2015 One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A. +2 more
core +2 more sources
Future Journal of Pharmaceutical Sciences, 2018 Objective: A simple, specific, accurate and economic reverse phase liquid chromatographic method was developed for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and tablet dosage form.
S.K. Mastanamma +3 more
doaj +1 more source
Liver transplantation for viral hepatitis in 2015 [PDF]
, 2016 Liver transplantation (LT) is a life-saving treatment for patients with end-stage liver disease and for patients with liver cell cancer related to liver disease.
Bortoluzzi, Ilaria +8 more
core +1 more source
Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study [PDF]
, 2017 Background: Since direct-acting antivirals (DAAs) have been approved for the treatment of hepatitis C virus (HCV) infection, a small series of patients with new-onset neuropsychiatric alterations have been referred to us.
Amodio, Piero +11 more
core +1 more source
Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C. [PDF]
Int J HepatolAim The use of direct‐acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later‐generation DAAs, glecaprevir (
Tawara S +10 more
europepmc +2 more sources
Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. [PDF]
, 2016 There have been dramatic advancements in the treatment of chronic hepatitis C (HCV) infection. This is largely due to the approval of several direct-acting antiviral agents (DAAs) from a variety of medication classes with novel mechanisms of action ...
Bidell, Monique R +4 more
core +2 more sources
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. [PDF]
PLoS ONE, 2016 BACKGROUND:Little is known on the cost-effectiveness of novel regimens for hepatitis C virus (HCV) compared with standard-of-care with pegylated interferon (pegIFN) and ribavirin (RBV) therapy in developing countries.
Guo-Feng Chen +34 more
doaj +1 more source